Gujarat Themis Biosyn: SEBI filings and ₹50cr vote

Gujarat Themis Biosyn Limited has reported a series of regulatory updates on stock exchanges in late March and early April 2026, including a postal ballot notice publication and a quarterly dematerialisation compliance certificate. The disclosures, made to BSE and NSE, are routine but important for investors tracking governance processes, related-party approvals, and compliance discipline.

The company, described in the filings as a manufacturer of fermentation-based active pharmaceutical ingredients (APIs) and intermediates, has also shared operating updates through its Q3FY26 results communication earlier in February 2026.

Share price snapshots shown alongside the filings

Alongside the announcements, the platform text shows multiple market snapshots for Gujarat Themis Biosyn. One screen lists a price of 372.75 with a move of -0.20 (-0.05%) “as on 05 May, 2026 | 02:35,” with a day range of 358.15 to 378.00.

Another market block shows the stock at 372.30 (noted “as on 24 Mar, 2026 | 09:27”). A separate section lists “Current Price ₹336” with Market Cap ₹3,659 Cr, High/Low ₹479/208, and Stock P/E 76.6.

Because these values appear as separate snapshots with different timestamps, they should be read as point-in-time references rather than a single consolidated quote.

Q4FY26 dematerialisation compliance certificate filed

On 8 April 2026, Gujarat Themis Biosyn submitted its quarterly certificate under SEBI Regulation 74(5) for the quarter ended 31 March 2026. The disclosure states that the certificate confirms proper handling of dematerialisation procedures.

The certificate was issued by the company’s registrar, MUFG Intime India Pvt. Ltd., and filed with both BSE and NSE. Such certificates are part of the routine compliance framework around securities held in demat form and related processing by the registrar and depositories.

Postal ballot notice published under SEBI listing rules

Earlier, Gujarat Themis Biosyn disclosed that it published a postal ballot notice in newspapers as required under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and also referenced Regulation 30.

The notice was published on Thursday, 19 March 2026, in Western Times (English) and Western Times (Gujarati). The company’s communication to exchanges was confirmed by Vineet Gawankar, Company Secretary and Compliance Officer.

What shareholders are being asked to approve

The postal ballot covered two items for shareholder consideration through remote e-voting.

First, the company proposed the re-appointment of Mrs. Kirandeept Madan (DIN: 00686547) as Non-Executive Woman Independent Director for a second term of five consecutive years. Her current term runs from May 1, 2021 to April 30, 2026, and the proposed term is May 1, 2026 to April 30, 2031. Her remuneration for FY 2025-26 is listed as ₹0.088 crore (₹8,80,000), and the disclosure states she attended 7 board meetings.

Second, the company sought approval for material related party transactions with Themis Medicare Limited (TML) for an aggregate value of ₹50 crore during FY 2026-27. The filing describes TML as a promoter group company holding 23.19% of Gujarat Themis Biosyn’s equity share capital.

Related-party transaction context disclosed by the company

The filing describes the proposed transactions as involving sale of fermentation-based APIs, intermediates, and other operational activities. It also states that the transactions are in the ordinary course of business and on an arm’s length basis, with pricing benchmarked to prevailing market prices and landed cost of products in India.

The disclosure includes past related-party activity values, including FY2024-25 sale of API ₹0.08 crore, FY2024-25 purchase of API ₹0.13 crore, FY2024-25 purchase of machinery ₹1.27 crore, FY2023-24 sale of API ₹1.64 crore, and FY2022-23 sale of API ₹0.37 crore.

E-voting process and the role of CDSL

For the postal ballot, Gujarat Themis Biosyn engaged Central Depository Services (India) Limited (CDSL) to provide the remote e-voting facility. The filing states voting will be conducted exclusively through electronic means, with no physical postal ballot forms distributed.

It also states that members whose names appear in the Register of Members or list of Beneficial Owners as on the cut-off date, and whose email addresses are registered with the company, registrar and transfer agent, or depositories, will be eligible to participate.

Key identifiers and filing references

Financial snapshot from Q3FY26 results (converted to ₹ crore)

In its Q3FY26 results update dated 5 February 2026, Gujarat Themis Biosyn reported revenue growth year-on-year, alongside a modest decline in net profit for the quarter. The filing also discussed completion of a new fermentation facility and work in its API block, including validation batches as part of a forward integration strategy.

The same update stated that R&D spend during the nine-month period was approximately 3% of revenue. It also disclosed an incremental impact of ₹0.1336 crore (₹13.36 lakhs) in Q3FY26 due to implementation of four Labour Codes notified by the Government of India on November 21, 2025.

For the nine months ended December 31, 2025, the company reported revenue from operations of ₹121.5898 crore, and net profit of ₹35.7903 crore.

Market impact: what these disclosures change, and what they do not

The SEBI Regulation 74(5) certificate filing is a compliance confirmation rather than a financial update. It typically does not change business operations, but it supports confidence that demat-related processes are being handled as per regulatory expectations.

The postal ballot is more consequential from a governance standpoint because it asks shareholders to vote on an independent director re-appointment and on the ceiling for related-party transactions. The ₹50 crore aggregate limit for FY2026-27, and the disclosure that Themis Medicare is a promoter group entity with a 23.19% holding, are the central investor-relevant points in that notice.

The trading and return figures shown in the text include two different “Historical Stock Returns” blocks. One shows 1 Day +2.40%, 5 Days +14.76%, 1 Month +64.08%, 6 Months -20.31%, 1 Year +34.87%, 5 Years +52.92%, while another shows 1 Day -3.21%, 5 Days +10.84%, 1 Month +44.39%, 6 Months -21.74%, 1 Year +27.71%, 5 Years +49.34%. These appear as separate snapshots and should be interpreted in the context of their respective capture times.

Why the sequence matters for investors tracking governance

The March postal ballot publication and the April demat compliance certificate together indicate an active cadence of exchange-facing governance and compliance disclosures. For minority shareholders, the clearest actionable item is the e-voting decision on the independent director term and the related-party transaction limit.

Separately, the February results note that the company has completed a new fermentation facility, and described steps such as validation batches in the API block and a hybrid wind-plus-solar captive power project in Gujarat. Those operational items provide context for why governance approvals and disclosure discipline can matter, particularly when capacity and business volumes expand.

Conclusion

Gujarat Themis Biosyn’s latest exchange updates cover two distinct areas: routine dematerialisation compliance for Q4FY26 and the process-driven steps of a postal ballot seeking approvals for board continuity and a ₹50 crore related-party transaction limit for FY2026-27. The next concrete milestone in this chain is the completion of the remote e-voting process as outlined in the postal ballot framework.